[go: up one dir, main page]

MX2009009207A - Metodos y composiciones para normalizar las secreciones de glandulas meibomianas. - Google Patents

Metodos y composiciones para normalizar las secreciones de glandulas meibomianas.

Info

Publication number
MX2009009207A
MX2009009207A MX2009009207A MX2009009207A MX2009009207A MX 2009009207 A MX2009009207 A MX 2009009207A MX 2009009207 A MX2009009207 A MX 2009009207A MX 2009009207 A MX2009009207 A MX 2009009207A MX 2009009207 A MX2009009207 A MX 2009009207A
Authority
MX
Mexico
Prior art keywords
methods
compositions
meibomian gland
gland secretions
normalizing
Prior art date
Application number
MX2009009207A
Other languages
English (en)
Inventor
George W Ousler Iii
Matthew J Chapin
Mark B Abelson
George Minno
Aron Shapiro
Original Assignee
Aciex Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aciex Therapeutics Inc filed Critical Aciex Therapeutics Inc
Publication of MX2009009207A publication Critical patent/MX2009009207A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención ofrece composiciones no acuosas para normalizar secreciones de glándulas meibomianas, y métodos de uso de ellas. La presente invención ofrece además composiciones y métodos para tratar y/o prevenir los signos y/o síntomas de enfermedad de resequedad ocular.
MX2009009207A 2007-02-28 2008-02-28 Metodos y composiciones para normalizar las secreciones de glandulas meibomianas. MX2009009207A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US90420907P 2007-02-28 2007-02-28
PCT/US2008/002762 WO2008106228A2 (en) 2007-02-28 2008-02-28 Methods and compositions for normalizing meibomian gland secretions

Publications (1)

Publication Number Publication Date
MX2009009207A true MX2009009207A (es) 2010-02-12

Family

ID=39462102

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009009207A MX2009009207A (es) 2007-02-28 2008-02-28 Metodos y composiciones para normalizar las secreciones de glandulas meibomianas.

Country Status (9)

Country Link
US (1) US20080312194A1 (es)
EP (1) EP2131809A2 (es)
JP (1) JP2010520210A (es)
CN (1) CN101668511A (es)
AU (1) AU2008219600A1 (es)
BR (1) BRPI0808410A2 (es)
CA (1) CA2679448A1 (es)
MX (1) MX2009009207A (es)
WO (1) WO2008106228A2 (es)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8569367B2 (en) 2004-11-16 2013-10-29 Allergan, Inc. Ophthalmic compositions and methods for treating eyes
US20080114423A1 (en) 2006-05-15 2008-05-15 Grenon Stephen M Apparatus for inner eyelid treatment of meibomian gland dysfunction
US7981095B2 (en) 2005-07-18 2011-07-19 Tearscience, Inc. Methods for treating meibomian gland dysfunction employing fluid jet
US20070016256A1 (en) 2005-07-18 2007-01-18 Korb Donald R Method and apparatus for treating gland dysfunction
US7981146B2 (en) 2006-05-15 2011-07-19 Tearscience Inc. Inner eyelid treatment for treating meibomian gland dysfunction
US20070060988A1 (en) 2005-07-18 2007-03-15 Grenon Stephen M Melting meibomian gland obstructions
US20090043365A1 (en) 2005-07-18 2009-02-12 Kolis Scientific, Inc. Methods, apparatuses, and systems for reducing intraocular pressure as a means of preventing or treating open-angle glaucoma
WO2013003594A2 (en) 2011-06-28 2013-01-03 Tearscience, Inc. Methods and systems for treating meibomian gland dysfunction using radio-frequency energy
US7981145B2 (en) 2005-07-18 2011-07-19 Tearscience Inc. Treatment of meibomian glands
US8950405B2 (en) 2006-05-15 2015-02-10 Tearscience, Inc. Treatment of obstructive disorders of the eye or eyelid
US8137390B2 (en) 2006-05-15 2012-03-20 Tearscience, Inc. System for providing heat treatment and heat loss reduction for treating meibomian gland dysfunction
US7976573B2 (en) 2006-05-15 2011-07-12 Tearscience, Inc. Inner eyelid heat and pressure treatment for treating meibomian gland dysfunction
US8128674B2 (en) 2006-05-15 2012-03-06 Tearscience, Inc. System for outer eyelid heat and pressure treatment for treating meibomian gland dysfunction
US7981147B2 (en) 2006-05-15 2011-07-19 Tearscience, Inc. Outer eyelid heat and pressure treatment for treating meibomian gland dysfunction
US8128673B2 (en) 2006-05-15 2012-03-06 Tearscience, Inc. System for inner eyelid heat and pressure treatment for treating meibomian gland dysfunction
US8007524B2 (en) 2006-05-15 2011-08-30 Tearscience, Inc. Heat treatment and heat loss reduction for treating meibomian gland dysfunction
US9314369B2 (en) 2006-05-15 2016-04-19 Tearscience, Inc. System for inner eyelid treatment of meibomian gland dysfunction
EP2187900B1 (en) * 2007-08-16 2016-11-09 The Schepens Eye Research Institute, Inc. Therapeutic compositions for treatment of inflammation of ocular and adnexal tissues
USD613408S1 (en) 2008-02-06 2010-04-06 Tearscience, Inc. Eye treatment head gear
USD617443S1 (en) 2008-02-06 2010-06-08 Tearscience, Inc. Eye treatment goggles
CA2764802A1 (en) * 2009-06-05 2010-12-09 Allergan, Inc. Artificial tears and therapeutic uses
USD638128S1 (en) 2009-10-06 2011-05-17 Tearscience, Inc. Ocular device design
PT2493474T (pt) * 2009-10-30 2019-11-26 Intratus Inc Métodos e composições para libertação prolongada de fármacos
KR20120115380A (ko) * 2010-01-11 2012-10-17 지티엑스, 인코포레이티드 마이봄선 기능 장애의 치료 방법
EP2591041A4 (en) * 2010-07-11 2013-11-27 Univ Arkansas COMPOSITIONS AND METHODS FOR INCREASING SLIP RATE AND EARLY POWER OF POULTRY
EP2624817A1 (en) * 2010-10-08 2013-08-14 Helperby Therapeutics Limited Novel composition
US20120093876A1 (en) * 2010-10-13 2012-04-19 Aciex, Inc. Ophthalmic Formulations, Methods Of Manufacture And Methods of Normalizing Meibomian Gland Secretions
US8957048B2 (en) * 2011-10-06 2015-02-17 Allergan, Inc. Compositions for the treatment of dry eye
US9907826B2 (en) 2011-12-07 2018-03-06 Allergan, Inc. Efficient lipid delivery to human tear film using a salt-sensitive emulsion system
PL2787969T3 (pl) * 2011-12-07 2021-12-20 Allergan, Inc. Skuteczne dostarczanie lipidów do ludzkiego filmu łzowego z zastosowaniem układu emulsji wrażliwej na sól
EP4494707A3 (en) * 2011-12-23 2025-04-23 University of Western Sydney Ophthalmic formulation
US8765725B2 (en) 2012-05-08 2014-07-01 Aciex Therapeutics, Inc. Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof
AU2013259872B2 (en) 2012-05-08 2018-06-28 Nicox Ophthalmics, Inc. Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof
WO2014008542A1 (en) * 2012-07-09 2014-01-16 Brien Holden Vision Institute Compositions, methods and/or devices for prevention and/or treatment of dry eye disorders
US10842670B2 (en) 2012-08-22 2020-11-24 Johnson & Johnson Vision Care, Inc. Apparatuses and methods for diagnosing and/or treating lipid transport deficiency in ocular tear films, and related components and devices
PT106679B (pt) 2012-11-27 2015-03-25 Hovione Farmaciencia Sa Formulações tópicas de tetraciclinas, sua preparação e usos
US9815865B2 (en) 2013-01-07 2017-11-14 Nicox Ophthalmics, Inc. Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof
US9763827B2 (en) 2013-04-30 2017-09-19 Tear Film Innovations, Inc. Systems and methods for the treatment of eye conditions
ES2942724T3 (es) 2013-04-30 2023-06-06 Alcon Inc Sistemas para el tratamiento de enfermedades del ojo
EP3015107B1 (en) * 2013-06-28 2019-08-28 Keio University Agent for treating meibomian gland dysfunction
WO2015134673A1 (en) * 2014-03-04 2015-09-11 The Trustees Of Columbia University In The City Of New York Method for treating ocular inflammation
US9463201B2 (en) 2014-10-19 2016-10-11 M.G. Therapeutics Ltd Compositions and methods for the treatment of meibomian gland dysfunction
US10279005B2 (en) 2014-11-25 2019-05-07 Allergan, Inc. Stabilized omega-3 ophthalmic compositions
KR102638112B1 (ko) * 2015-02-02 2024-02-20 산텐 세이야꾸 가부시키가이샤 폴리아프론 및 이의 안검 투여
JP2018533622A (ja) * 2015-09-28 2018-11-15 アズーラ オフサルミックス エルティーディー． マイボーム腺の脂質分泌を増加させるためのチオールおよびジスルフィド含有薬剤
AU2017250509B2 (en) 2016-04-14 2023-03-02 Azura Ophthalmics Ltd. Selenium disulfide compositions for use in treating meibomian gland dysfunction
US10974063B2 (en) 2016-06-30 2021-04-13 Alcon Inc. Light therapy for eyelash growth
US11478437B2 (en) 2016-07-05 2022-10-25 Jenivision Inc. Formulations for hair growth
CA3032695C (en) 2016-08-19 2021-11-23 Akrivista, LLC Methods of diagnosing and treating dry eye syndrome and compositions for treating a human eye
KR20200037230A (ko) * 2017-06-30 2020-04-08 제니비젼 인크. 모발 성장용 제제
US11622982B2 (en) 2017-08-18 2023-04-11 Akrivista Llc Methods of diagnosing and treating dry eye syndrome and compositions for treating a human eye
US11759472B2 (en) 2017-11-21 2023-09-19 Cs Pharmaceuticals Limited Compositions and methods of use for treating aberrant inflammation in peri-ocular secretory glands or at the ocular surface
CN111372564B (zh) * 2017-11-21 2024-10-15 创盛桥康制药有限公司 用于治疗眼周分泌腺中或眼表上的异常发炎的组合物和方法
JP6904289B2 (ja) * 2018-03-19 2021-07-14 ライオン株式会社 水性眼科用組成物
US10933111B2 (en) 2019-01-08 2021-03-02 Boston Biotechnology US CORP Treating dry eye disorders
CN115279458A (zh) 2020-01-10 2022-11-01 阿祖拉眼科有限公司 组合物和敏感性说明
WO2022026805A1 (en) * 2020-07-31 2022-02-03 Altaire Pharmaceuticals, Inc. Ophthalmic compositions for removing meibum or inhibiting meibum buildup
WO2022109497A1 (en) 2020-11-23 2022-05-27 Sight Sciences, Inc. Formulations and methods for treating conditions of the eye
FR3131214A1 (fr) * 2021-12-23 2023-06-30 Laboratoires Thea Composition topique et son applicateur, destines a soulager le chalazion

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2804421A (en) * 1951-04-24 1957-08-27 American Cyanamid Co Tetracycline type antibiotic ointment
US3642987A (en) * 1969-12-23 1972-02-15 Malcolm E Bergy Lincomycin and tetracycline compositions
EP0028110B1 (en) * 1979-10-26 1984-03-07 Smith and Nephew Associated Companies p.l.c. Autoclavable emulsions
US4407791A (en) * 1981-09-28 1983-10-04 Alcon Laboratories, Inc. Ophthalmic solutions
US4454151A (en) * 1982-03-22 1984-06-12 Syntex (U.S.A.) Inc. Use of pyrrolo pyrroles in treatment of ophthalmic diseases
US5149694A (en) * 1988-03-09 1992-09-22 Alcon Laboratories, Inc. Combination of tobramycin and dexamethasone for topical ophthalmic use
US4923699A (en) * 1988-06-03 1990-05-08 Kaufman Herbert E Eye treatment suspension
US4960799A (en) * 1988-09-13 1990-10-02 Ciba-Geigy Corporation Stabilized aqueous solutions of pharmaceutically acceptable salts of ortho-(2,6-dichlorophenyl)-aminophenylacetic acid for opthalmic use
US5122519A (en) * 1989-06-27 1992-06-16 American Cyanamid Company Stable, cosmetically acceptable topical gel formulation and method of treatment for acne
EP0543811B1 (en) * 1990-08-16 2000-07-12 Bloom, Leonard Topical treatment of blepharitis
DE69940227D1 (de) * 1998-05-08 2009-02-12 Univ Miami Verwendung von sub-antimikrobiellen tetracyclinen zur Behandlung von okularer Rosacea
US6432934B1 (en) * 1998-08-06 2002-08-13 Advanced Vision Research Methods and compositions for topical treatment of eye surface inflammation and related dry eye disease
US6254860B1 (en) * 1999-04-13 2001-07-03 Allergan Sales, Inc. Ocular treatment using cyclosporin-A derivatives
IT1313610B1 (it) * 1999-08-09 2002-09-09 S I F I Societa Ind Farmaceuti Processo per la preparazione di formulazioni acquose per uso oftalmico
JP3677421B2 (ja) * 1999-12-27 2005-08-03 扶桑薬品工業株式会社 涙液分泌促進組成物
US6967023B1 (en) * 2000-01-10 2005-11-22 Foamix, Ltd. Pharmaceutical and cosmetic carrier or composition for topical application
FR2823441B1 (fr) * 2001-04-12 2004-09-10 Thea Lab Composition pharmaceutique a base de macrolides pour application locale en ophtalmologie et son procede de preparation
MXPA03009995A (es) * 2001-05-09 2004-06-30 Univ Michigan Uso de composiciones para tratar rosacea.
WO2003005971A2 (en) * 2001-07-13 2003-01-23 Paratek Pharmaceuticals, Inc. Tetracycline compounds having target therapeutic activities
US6494856B1 (en) * 2001-09-12 2002-12-17 Unilever Home & Personal Care Usa, Division Of Conopco, Inc. Swab deliverable actives
US6488646B1 (en) * 2001-09-12 2002-12-03 Unilever Home & Personal Care Usa Swab deliverable actives
US7008631B2 (en) * 2002-04-16 2006-03-07 Collagenex Pharmaceuticals, Inc. Methods of simultaneously treating ocular rosacea and acne rosacea
KR101059711B1 (ko) * 2003-01-21 2011-08-29 센주 세이야꾸 가부시키가이샤 2-아미노-3-(4-브로모벤조일)페닐아세트산 함유 수성액제
DK1615622T3 (da) * 2003-04-07 2012-10-15 Supernus Pharmaceuticals Inc Doxycyclinpræparater til indgivelse én gang dagligt
DK1755616T3 (da) * 2004-04-08 2013-11-25 Eye Co Pty Ltd Behandling af ekssudativ retinopati med mineralkortikoider
WO2008097851A1 (en) * 2007-02-02 2008-08-14 Warner Chilcott Company, Inc. Tetracycline compositions for topical administration

Also Published As

Publication number Publication date
CN101668511A (zh) 2010-03-10
JP2010520210A (ja) 2010-06-10
CA2679448A1 (en) 2008-09-04
US20080312194A1 (en) 2008-12-18
WO2008106228A2 (en) 2008-09-04
BRPI0808410A2 (pt) 2015-06-23
WO2008106228A3 (en) 2009-03-12
AU2008219600A1 (en) 2008-09-04
EP2131809A2 (en) 2009-12-16

Similar Documents

Publication Publication Date Title
MX2009009207A (es) Metodos y composiciones para normalizar las secreciones de glandulas meibomianas.
WO2012051313A3 (en) Ophthalmic formulations, methods of manufacture and methods of normalizing meibomian gland secretions
MX2009009761A (es) Composiciones y estuches para tratamiento de la influenza.
IN2012DN03883A (es)
CA2865011C (en) Methods and compositions for treating huntington's disease
CR20140422A (es) Composiciones de enzima digestiva estable
MX2009012625A (es) Metodos para el tratamiento, diagnostico y deteccion de trastornos asociados con el fgf21.
WO2007092622A3 (en) Compositions and methods for treating bone
IN2012DN00624A (es)
MX2009008347A (es) Oxabicicloheptanos y oxabicicloheptenos, su preparacion y uso.
EA200901166A1 (ru) Соединения и композиции в качестве модуляторов активности gpr 119
WO2008016643A3 (en) Certain chemical entities, compositions, and methods
MX2009006536A (es) Compuestos de heteroaril-heteroarilo como inhibidores de cdk para el tratamiento de cancer, inflamacion e infecciones virales.
GEP20084520B (en) Use of retinyl derivatives and compositions thereof for treating ophthalmic diseases
MY172151A (en) Certain chemical entities, compositions and methods
MX2009011002A (es) Composiciones de proteccion de isquemia/reperfusion y metodos de uso.
MY172372A (en) Compositions and methods for lowering triglycerides
MX2009008430A (es) Anticuerpos anti-robo4 y sus usos.
ATE449097T1 (de) Pyridoä2,3-düpyrimidin-2,4-diamin-verbindungen als ptpib-hemmer
EA201200323A1 (ru) Соединения и композиции, как ингибиторы протеинкиназы
MX2010001692A (es) Ciertas entidades quimicas, composiciones y metodos.
MX379016B (es) Composiciones y metodos para tratar enfermedad de gaucher.
DOP2011000386A (es) Antagonistas de la trayectoria hedgehog de ftalazina disustituida
MY147247A (en) Organic compounds and their uses
MX2010000098A (es) Derivados de guanina policiclicos y sus metodos de uso.